Interferon Alpha Plus 13-Cis-Retinoic Acid Modulation of BCL-2 Plus Paclitaxel for Recurrent Small Cell Lung Cancer (SCLC): An Eastern Cooperative Oncology Group Study (E6501)

BACKGROUND: Patients with recurrent small cell lung cancer (SCLC) have dismal outcomes. The failure of salvage therapy is due to the possible development of resistance mechanisms, such as the upregulation of the anti-apoptosis protein, Bcl-2. We conducted a phase II study to evaluate if modulation o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Chemother Pharmacol
Main Authors: Pillai, Rathi N., Aisner, Joseph, Dahlberg, Suzanne E., Rogers, John S., DiPaola, Robert S., Aisner, Seena, Ramalingam, Suresh S., Schiller, Joan H.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4296897/
https://ncbi.nlm.nih.gov/pubmed/24858462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2427-7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares